|Articles|August 1, 2002
- Applied Clinical Trials-08-01-2002
Developing New Drugs in 1000 Days
Everybody wants faster cycles and and quicker turnarounds with NDAs. In the U.S., will it soon be possible to go from testing to approval in 1000 days?
Advertisement
Articles in this issue
about 24 years ago
Cross-(Dys)Functional Teamsabout 24 years ago
Checking In on Children, Checking Up on Filesabout 24 years ago
eSource Reduxabout 24 years ago
New User Fee Program Aims to Spur Drug Developmentabout 24 years ago
Paper vs. Electronic DiariesAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection
2
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
3
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
4
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
5